Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pp65-shLAMP DC
- Development stage
- Phase 2
- Lead developer
- Immunomic Therapeutics
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal
01
Overview
pp65-shLAMP DC is an investigational therapeutic cancer vaccine designed for the treatment of glioblastoma and glioblastoma multiforme. It is a dendritic cell therapy in which patient-derived dendritic cells are loaded with messenger RNA encoding the human cytomegalovirus (CMV) matrix protein pp65 and a short-length lysosomal-associated membrane protein (shLAMP). The inclusion of LAMP targets the antigen to the lysosome for enhanced presentation via MHC class II molecules to T-cells. This process aims to stimulate a robust immune response against tumor cells expressing CMV antigens. The vaccine is administered after priming with tetanus-diphtheria toxin and has been evaluated in phase 1 and phase 2 clinical trials for safety, feasibility, immunogenicity, and efficacy in patients with newly diagnosed or recurrent glioblastoma[1][2][3][5][6][7].
- Other names
- autologous CMV-pp65-shLAMP-1 mRNA loaded dendritic cell vaccineLAMP-pp65-DC vaccineLAMP-pp-65-DC vaccineLAMP-pp 65-DC vaccineHuman CMV pp65-LAMP mRNA-pulsed autologous DCs
02
Targets
pp65 (Cytomegalovirus phosphoprotein 65)
Beyond the preview
Go deeper on pp65-shLAMP DC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pp65-shLAMP DC.